School of Medicine
Showing 1-10 of 30 Results
-
Lucia Aronica
Casual Employee, Medicine - Med/Stanford Prevention Research Center
BioDr. Lucia Aronica is an epigenetics and nutrigenomics scientist at Stanford University School of Medicine with over 17 years of research experience. She created Stanford's first courses in nutritional epigenetics and longevity medicine, and developed "epinutrition," a framework for optimizing gene expression through diet.
Featured in the 2024 Netflix documentary "You Are What You Eat: A Twin Experiment," Dr. Aronica is a TEDx speaker who presents to 10,000+ clinicians annually. She has published 25+ peer-reviewed papers in top journals including Cell and BMC Medicine, and secured over $1 million in competitive research funding.
Dr. Aronica received her PhD in epigenetics from the University of Vienna (2010) and conducted research at Oxford and USC. She serves on scientific advisory boards in precision health and longevity medicine. -
Thomas Glynn
Adjunct Lecturer, Medicine - Med/Stanford Prevention Research Center
BioBiosketch - Thomas J. Glynn, M.A., M.S., Ph.D. (psych.)
Dr. Glynn is, from 2014 to the present, Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine and Executive Team Member, Mayo Clinic Global Bridges Initiative. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS). In these positions, he advised the ACS about emerging research and policy issues in cancer prevention and control, recommended cancer prevention and control research and policies, and participated in the development of an international cancer control program aimed at promoting cancer prevention-related research, advocacy, treatment, and policy change, particularly in middle- and low-income nations.
Prior to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute's (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI's Cancer Control Extramural Research Branch. There, he directed a national program of research aimed at reducing the incidence and prevalence of cancer, primarily through dietary change, tobacco use reduction, and adherence to cancer screening guidelines. From 1983 to 1991, he was Research Director for the NCI's Smoking, Tobacco, and Cancer Program and from 1978 to 1983, he was a Research Psychologist at the National Institute on Drug Abuse.
Dr. Glynn has published widely on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education and is co-developer of the 4A (now 5A) protocol for the treatment of tobacco dependence. In addition to his work at the ACS and NCI, he has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, the WHO, a variety of pharmaceutical organizations, and national, state and local governments.
He has also served as a Senior Scientific Reviewer for the U.S. Surgeon General's Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. He is a Fellow of the Society for Research on Nicotine and Tobacco and his awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the Society for Research on Nicotine and Tobacco John Slade Award, and the American Society of Preventive Oncology Joseph W. Cullen Memorial Award. -
Michaela Kiernan
Sr Research Scholar, Medicine - Med/Stanford Prevention Research Center
Current Research and Scholarly InterestsResearch interests include the design and experimental testing of innovative strategies to improve recruitment and retention of randomized clinical trials.
